Fresenius Kabi expands its critical care portfolio in the U.S.

Fresenius Kabi expands its portfolio of critical care medicines by launching Vasopressin Injection, USP, a generic equivalent to Vasostrict®* in the U.S. 

Fresenius Kabi Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. 

* Vasostrict® is a registered trademark of Par Pharmaceutical.